| Nov 6 |
Catalyst: Q3 Earnings Snapshot
|
| Nov 6 |
Catalyst Pharmaceuticals Non-GAAP EPS of $0.57 beats by $0.06, revenue of $128.7M beats by $5.28M
|
| Nov 6 |
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Nov 6 |
CPRX vs. STVN: Which Stock Is the Better Value Option?
|
| Nov 5 |
Catalyst Pharmaceuticals Q3 2024 Earnings Preview
|
| Nov 4 |
Are Medical Stocks Lagging Bioventus (BVS) This Year?
|
| Oct 22 |
Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
|
| Oct 17 |
High Growth Tech Stocks to Watch in October 2024
|
| Oct 10 |
With 75% ownership of the shares, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is heavily dominated by institutional owners
|
| Oct 8 |
Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts
|
